FT-022

FT-022 is an investigational **rAAV gene therapy** being developed by **Fronterra** for **Parkinson's disease**. Public pipeline information identifies the program as a **preclinical** neurology asset within Fronterra's broader recombinant adeno-associated virus platform. The specific transgene, molecular target, and detailed mechanistic design have not been publicly disclosed, so the available evidence supports describing FT-022 as a preclinical gene therapy candidate intended for Parkinson's disease rather than a target-defined product.

Other names

FT-022 Fronterra rAAV gene therapyFT022 Fronterra rAAV gene therapyFT 022 Fronterra rAAV gene therapy